Unexpectedly high percentages of anti-TIF-1γ antibodies detected by Euroline in patients without DM dilutes the usefulness of anti-TIF-1γ as a myositis-specific antibody (1, 2, 6, 20, 21) and so reinforces the clinician’s role in correct DM diagnosis. This evidence concerns the gene TRIM33 and dermatomyositis.